Rapport Therapeutics (RAPP) Director Young Buys $100K of Stock

Director Wendy B. Young purchased 3,789 shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP) on October 22, 2026, according to a Form 4 filing with the SEC. The shares were bought at a price of $26.39 per share, totaling roughly $99,992.

RAPP Rapport Therapeutics, Inc.

$25.06 ▼ -10.85% year to date

1M 3M YTD

Daily close · Oct 21, 2026

Inside Wendy B. Young's Rapport Therapeutics Trade

Following the open-market purchase, Young held a total of 13,289 shares in the clinical-stage biotechnology company. This transaction lifted her personal holdings by about 39.9% from her prior position. The stock closed at $26.53 on the day of the trade.

Other Institutional Activity in Rapport Therapeutics

Trv Gp V, LLC reduced its stake by 854,814 shares, ending the period with 6,280,525 shares valued at about $166.6 million. Arch Venture Management, LLC kept its holdings steady at 3,728,738 shares worth roughly $98.9 million. Capital International Investors trimmed its position by 175,962 shares to hold 2,921,958 shares valued at about $77.5 million. Cormorant Asset Management, LP lowered its holdings by 299,881 shares, finishing with 2,657,521 shares worth about $70.5 million. Sofinnova Investments, Inc. maintained its position unchanged with 1,904,408 shares valued at roughly $50.5 million.

Rapport Therapeutics, Inc. Stock Up 5.9%

RAPP shares recently traded at $26.53 as of October 22, 2026. The stock sits below its 50-day moving average of $39.90 and below its 200-day moving average of $35.75. Over the past year, shares have ranged from a low of $23.75 to a high of $52.93.

Recent Earnings

Rapport Therapeutics reported trailing-twelve-month revenue of $20.0 million and a trailing EPS of -$3.03. The company posted a return on equity of -40.0% and a net margin of 0.0%. The company focuses on developing small molecule medicines for central nervous system disorders and has a quick ratio of 15.35 and a current ratio of 15.72, reflecting its cash reserves relative to obligations. The firm is scheduled to release its next financial results on November 5, 2026.

Insider Buying and Selling at Rapport Therapeutics, Inc.

Other executives have also transacted in company stock recently. Chief Operating Officer Cheryl Gault sold 10,000 shares on September 30, 2026, for about $331,856. Chief Executive Officer Abraham N. Ceesay disposed of 4,522 shares on October 7, 2026, valued at roughly $143,273. Chief Financial Officer Troy A. Ignelzi bought 5,500 shares on October 21, 2026, at $26.10 per share for a total value of $143,550.

Analysts Set New Price Targets

HC Wainwright & Co. reiterated a buy rating with a $66.00 target on October 20, 2026. BTIG maintained a buy rating while raising its target from $75.00 to $89.00 on October 20, 2026. Jones Trading maintained a buy rating and lifted its target from $50.00 to $82.00 on October 21, 2026. Wells Fargo maintained an overweight rating and adjusted its target from $51.00 to $50.00 on October 21, 2026. Guggenheim maintained a buy rating while raising its target from $65.00 to $70.00 on October 21, 2026. Overall, the stock carries a consensus strong buy rating from 15 analysts with a mean price target of $69.46.

About Rapport Therapeutics

Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise based in Boston, Massachusetts. The firm discovers and develops transformational small molecule medicines aimed at helping patients with central nervous system disorders. Insider transactions like director purchases draw attention as the company advances its clinical pipeline toward upcoming milestones.

Bottom Line

Investors are keeping an eye on upcoming financial disclosures, particularly the earnings report scheduled for November 5, 2026. Monitoring further Form 4 filings will show whether executive buying trends continue ahead of clinical updates.